Arvanil is an agonist at transient receptor potential vanilloid 1 (TRPV1) channels and cannabinoid 1 (CB1) receptors. Arvanil exhibits antidepressant, hypertensive, immunosuppressive, anti-inflammatory, antiemetic, and anticancer activities. Arvanil decreases immobility time in vivo in the forced swim test and tail suspension test. In other animal models, arvanil increases lung tidal volume, diaphragm activity, and mean arterial blood pressure. Additionally, arvanil inhibits lymphocyte proliferation and production of IFN-γ, inhibiting the G1/S phase transition in polymorphonuclear blood cells. Arvanil also ameliorates experimental autoimmune encephalitic (EAE) pathology in vivo. This compound inhibits proliferation in breast cancer and prostate cancer cells as well.